Horowitz, John

Apixaban versus warfarin in patients with atrial fibrillation

Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 8,943

Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure

Packer, M., Poole-Wilson, P. A., Armstrong, P. W., Cleland, J. G. F., Horowitz, J. D., Massie, B. M., Rydén, L., Thygesen, K., & Uretsky, B. F. (1999) · Circulation

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 1,244

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation

Hijazi, Z., Wallentin, L., Siegbahn, A., Andersson, U., Christersson, C., Ezekowitz, J., Gersh, B. J., Hanna, M., Hohnloser, S., Horowitz, J., et al. (2013) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management

Cited by 231

Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial

Stewart, S., Ball, J., Horowitz, J. D., Marwick, T. H., Mahadevan, G., Wong, C., Abhayaratna, W. P., Chan, Y. K., Esterman, A., Thompson, D. R., et al. (2015) · The Lancet

Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management

Cited by 147

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 118

Aging of the Nitric Oxide System: Are We as Old as Our NO?

Sverdlov, A. L., Ngo, D. T. M., Chan, W. P. A., Chirkov, Y. Y., & Horowitz, J. D. (2014) · Journal of the American Heart Association

Nitric Oxide and Endothelin EffectsCardiovascular Health and Disease Prevention

Cited by 97

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Bohula, E. A., Scirica, B. M., Inzucchi, S. E., McGuire, D. K., Keech, A. C., Smith, S. R., Kanevsky, E., Murphy, S. A., Leiter, L. A., Dwyer, J. P., et al. (2018) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 94

Interplay between Oxidative Stress and Inflammation in Cardiometabolic Syndrome

Sverdlov, A. L., Figtree, G. A., Horowitz, J. D., & Ngo, D. T. M. (2016) · Mediators of Inflammation

Adipokines, Inflammation, and Metabolic DiseasesNitric Oxide and Endothelin Effects

Cited by 40

Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite

Maher, A. R., Arif, S., Madhani, M., Abozguia, K., Ahmed, I., Fernandez, B. O., Feelisch, M., O'Sullivan, A., Christopoulos, A., Sverdlov, A. L., et al. (2013) · British Journal of Pharmacology

Nitric Oxide and Endothelin EffectsHeart Failure Treatment and Management

Cited by 26